Treatment for relapsed or refractory T-cell acute leukemia/lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy of a combination therapy using Venetoclax, Homoharringtonine, Cytarabine, and G-CSF in patients with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). It is a prospective, single-arm, phase II study aiming to enroll 50 participants. The primary goal is to achieve complete remission, with or without recovery of peripheral blood cells. The study addresses a critical need for effective treatments in a patient population with a low overall survival rate.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Before enrollment, a diagnosis of newly diagnosed T-cell acute leukemia/lymphoma.The diagnostic criteria refer to the 2022 WHO classification; 2. Age ≥ 14 years,\<75 years; 3. Clincally diagnosed as relapsed or refractory T-ALL/LBL; 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; 5. Expected survival time ≥ 2 months; 6. No organ dysfunction that would restrict the use of this protocol during the screening period; 7. Understand the study and sign the informed consent form.

Exclusion Criteria:

* 1\. Patients with known central nervous system (CNS) involvement of T-ALL/LBL; 2. Diseases with abnormal heart, lung, liver, kidney, or other organ functions that may limit the patient's participation in this trial (including but not limited to severe infections, uncontrolled diabetes, severe heart failure or angina, active pulmonary tuberculosis, asthma, COPD, bronchiectasis, etc.) 3. Cardiac ultrasound LVEF \< 45%; 4. History of other malignancies within the past 5 years, excluding localized thyroid cancer and in situ skin cancer; 5. Serum total bilirubin \> 1.5 ULN (upper limit of normal); ALT or AST \> 2.5 ULN; serum creatinine \> 1.5 ULN; 6. Known HIV infection; 7. Conditions affecting the use of the study drug as assessed by the investigator; 8. Inability to understand or comply with the study protocol.

Where it's running

• The First Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Jie Jin, M.D.
• Email: jiej0503@163.com
• Phone: +8657187236896

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belumosudil vs. Ruxolitinib for hepatic cGVHD after HSCT

  This trial tests whether belumosudil or ruxolitinib works better for hepatic chronic GVHD after a stem cell transplant in people 12 and older.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07794514

• Gastric protection after transplant: switch from PPI to teprenone to see effects on GVHD

  This trial tests whether switching from a proton pump inhibitor to teprenone after allogeneic HSCT changes the risk of acute graft-versus-host disease in patients with hematologic cancers.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou · NCT07791849

• Gut microbes and blood signals in sepsis-related liver and kidney injury

  This study tests whether gut microbes and blood markers differ in adults with sepsis who develop liver or kidney injury, compared with healthy volunteers.

  Recruiting at 6 sites First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang and 5 other locations · NCT07735182

• Eculizumab for high-risk TA-TMA in adult HSCT recipients

  This trial tests whether eculizumab can help adults with high-risk TA-TMA after allogeneic stem cell transplantation.

  Recruiting at 8 sites Phase 2 First Affiliated Hospital of Zhejiang University · Changsha, Hunan and 7 other locations · NCT07707687

• Single-dose vs divided-dose G-CSF for healthy stem cell donors

  This study tests whether giving G-CSF as one daily dose or split into two doses helps healthy donors mobilize enough stem cells for transplantation.

  Recruiting at 8 sites Phase 3 First Affiliated Hospital of Zhejiang University · Changsha, Hunan and 7 other locations · NCT07692841

• BY002 safety in healthy adults: a first-in-human, randomized, placebo-controlled study

  This study tests BY002 against placebo to see if it is safe and tolerable in healthy adults.

  Recruiting Phase 1 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07640438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.